SEATTLE, Aug. 18, 2021 (GLOBE NEWSWIRE) -- Global Myocardial Infarction Market to Surpass US$ 2,714.8 Million by 2028, Says Coherent Market Insights (CMI)
According to Coherent Market Insights, the global myocardial infarction market is estimated to be valued at US$1,816.8 million in 2021 and is expected to exhibit a CAGR of 5.9 % during the forecast period (2021-2028).
Key Trends and Analysis of the Global Myocardial Infarction Market:
Key trends in the market include increasing cases of cardiovascular diseases, increasing number of product launches, and increase in awareness programs on cardiovascular diseases.
Increasing prevalence of cardiovascular diseases is expected to fuel drive the global myocardial infarction market over the forecast period. For instance, according to the World Health Organization (WHO), cardiovascular diseases (CVDs) are the leading cause of death throughout the world. In 2019, an estimated 17.9 million people died from CVDs, accounting for 32% of all global deaths. 85 %of these deaths were caused by a heart attack or a stroke.
The increasing number of product approvals and launches is expected to drive the growth of the global myocardial infarction market. For instance, on October 13, 2020, Cadila Pharmaceuticals Ltd., one of the largest private pharmaceutical companies in India, launched Tikacad, an antiplatelet drug containing ticagrelor, a P2Y12 platelet inhibitor that is believed to reduce the rate of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome (ACS) or history of myocardial infarction (MI).
Request for Sample copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/4585
Increasing number of public initiatives and awareness program on cardiovascular disease is expected to drive the growth of the global myocardial infarction market. For instance, on February 3, 2021, The American Heart Association, the world's largest volunteer organization dedicated to fighting heart disease and stroke, encouraged women in the U.S. to wear red on National Wear Red Day on February 5, 2021 to raise awareness that one in every three women dies from cardiovascular disease. Women (and men) are encouraged to wear red to raise awareness of heart disease as a part of the American Heart Association's signature campaign, Go Red for Women, which is sponsored nationally by CVS (consumer value stores) Health and supported by Big Lots.
Key Market Takeaways:
Increasing research and development activities, rising product launches and approvals, inorganic activities such as collaborations, agreements, acquisitions, and others are expected to drive growth of the global myocardial infarction market over the forecast period. For instance, on May 26, 2020, Boehringer Ingelheim and Eli Lilly and Company, two of the most important pharmaceutical organizations in the world, introduced an academic research collaboration with the Duke Clinical Research Institute (DCRI), an academic clinical research organization, on a brand new trial, EMPACT-MI. The collaboration will investigate whether or not empagliflozin can improve results and prevent coronary heart failure in adults with or without diabetes with a history of acute myocardial infarction that is heart attack.
Competitive Landscape:
Key players operating in the global myocardial infarction market include Bristol-Myers Squibb Co., Bayer AG, Johnson & Johnson Services Inc., Sanofi S.A., Novartis International AG, AstraZeneca plc., Daiichi Sankyo Co Ltd, Boehringer Ingelheim International GmbH, Pfizer Inc., and Merck KGaA.
Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/4585
Market Segmentation:
- Global Myocardial Infarction Market, By Drug Class:
- Antiplatelet Agents
- Glycoprotein IIb/IIIa Inhibitors
- Antithrombotic Agents
- Beta-adrenergic Blockers
- Vasodilators
- Angiotensin-converting Enzyme (ACE) Inhibitors
- Angiotensin-receptor Blockers
- Analgesics
- Thrombolytics
- Global Myocardial Infarction Market, By Route of Administration:
- Oral
- Injectable
- Global Myocardial Infarction Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Myocardial Infarction Market, By Region:
- North America
- By Country:
- U.S.
- Canada
- By Country:
- Latin America
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- By Country:
- Europe
- By Country:
- U.K.
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- By Country:
- Asia Pacific
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- By Country
- Middle East
- By Country:
- GCC
- Israel
- Rest of Middle East
- By Country:
- Africa
- By Country/Region:
- South Africa
- Central Africa
- North Africa
- By Country/Region:
- North America
Related Market Intelligence Reports:
Cardiac Biomarkers Market, by Product Type (Myocardial Muscle Creatine Kinase (CK-MB), Troponins (T and I), Myoglobin, Brain Natriuretic Peptide (BNPs) or NT-proBNP, Ischemia-modified Albumin (IMA), and Others), by Application (Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome, Atherosclerosis, and Others), by Location of Testing (Laboratory Testing and Point-of-Care Testing), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028
Preclinical Isolated Organ Perfusion System Market, by Type (Isolated Heart Perfusion Systems, Isolated Abdominal Organ Perfusion Systems, Isolated Lung Perfusion Systems and Others), by End User (Industrial Laboratories and CROs and Academic and Government Research Institutes), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 – 2027
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide.
